NEW YORK (GenomeWeb News) – Proteomics firm ProteoMedix said today that it has closed on a Series B equity funding round, raising CHF 3.2 million ($3.62 million) from existing and new investors.

The Zurich-based company, which spun out of the lab of Swiss Federal Institute of Technology researcher Ruedi Aebersold in 2010, plans to use the funds to continue development of its lead product, a protein test for aiding detection of prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.